A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q) Leukemia (2013) 27, 1610-1613; doi:10.1038/leu.2013.59 E3 ubiquitin ligase protein Cereblon (CRBN) has been identified as a direct molecular target for the teratogenicity of thalidomide and cytotoxicity of immunomodulatory drugs (IMiDs) such as lenalidomide.
1,2 CRBN gene is highly conserved and its related protein of 442 AA is ubiquitously expressed in humans. CRBN is part of a functional E3 ubiquitin ligase complex together with the DNA damage-binding protein-1 (DDB1), Cullin 4A and Roc1, and acts as a substrate receptor for client proteins to be ubiquitinated and degraded by proteasome. 1 CRBN itself undergoes autoubiquitination, and thalidomide is described as an inhibitory molecule for CRBN auto-ubiquitination activity.
Thalidomide or lenalidomide have demonstrated their efficacy in the treatment of various hematological disorders including myeloma 3 and myelodysplastic syndromes (MDS), either with or without deletion of 5q chromosome. [4] [5] [6] It has been recently shown that changes in gene expression patterns induced by lenalidomide are abrogated by the depletion of CRBN gene in myeloma cell lines. 7 Furthermore, 485% patients with low expression of CRBN are resistant to treatment with thalidomide, and, conversely, high CRBN gene levels correlate with better survival in myeloma patients treated with maintenance thalidomide. 7, 8 In low/int-1 risk MDS, the erythroid response rate to thalidomide is quite low (16-30%) and responses are usually short, 9 whereas patients with low/int-1 risk MDS with del5q have a high response rate (50-67%) to lenalidomide. 5, 10 By contrast, 430% of low/int-1 MDS patients without del(5q) respond to this treatment. 6, 11 Altogether, these data provided us with a rationale to investigate the role of CRBN gene in the response to lenalidomide in low/int-1 MDS patients without del(5q).
Sixty-six MDS patients from five hematological centers with low/ int-1 risk MDS without del5q were included in this study between January 2010 and December 2012. All patients were anemic and resistant to erythropoiesis-stimulating agents either epoetin alpha/beta (60 000 U/week) or darbopoetin (300 mg/week) during 12 weeks, and remained transfusion dependent (X4U of Red Blood Cells during the previous 8 weeks). They received a dose of 10 mg/ day of lenalidomide for 21 days every 28 days, and the erythroid response rate, hematological improvement-erythroid was evaluated according to the IWG 2006 criteria after at least 3 months of treatment. Fifteen patients were not evaluable due to treatment toxicity or early death. The characteristics of the 51 remaining patients who completed 3 months of treatment (26 RARS, 8 RCMD-RS, 7 RCMD, 4 RA, 5 RAEB-1 and 1 CMML) are described in Table 1 International Prognostic Scoring System (IPSS; P ¼ 0.324) at treatment onset was observed between the two groups. The overall response rate was equivalent to that reported in the literature. 6, 11 The CRBN gene located in 3p26.2 contains 11 predicted exons. To address the putative role of CRBN in the response to lenalidomide in MDS patients, we conducted genetic studies Accepted article preview online 26 February 2013; advance online publication, 26 April 2013 including comparative genomic hybridization (CGH) and Sanger sequencing to search for deletion or mutation of CRBN gene. Genomic DNA from six responders (two RARS, two RCMD, two RCMD-RS) and six nonresponders (three RARS, two RCMD, one RCMD-RS) were analyzed by CGH. Copy number variations have been detected in six patients, gains in four patients at chr2q33.1, 6q26, 7q34 and 17q25.3, a deletion of chr11 in one patient (also detected by the karyotype analysis) and a micro-deletion at chr10q21 in one patient. No deletion/gain of the 3p26.2 region has been identified. Furthermore, the regions encoding for CRBN putative partners (DDB1, DDB2, CUL4A, CUL4B, RBX1, DCAF4L1, DCAF4L2, DCAF5, DCAF6, DCAF7, DCAF8, DCAF8L1, DCAF10, DCAF11, DCAF12, DCAF12L1, DCAF12L2, DCAF13, DCAF15, DCAF16, DCAF17, DDA1 and RP11-574F21.3) were normal.
CRBN gene entire coding sequence and part of the promoter region upstream the 5 0 -untranslated region were sequenced in 12 patients including 6 responders and 6 nonresponders. We found no nucleotide changes in the coding sequence except for a synonymous change at nucleotide 3197918 in exon 6 corresponding to tyrosine 244 in one case. Then, we analyzed the distribution of the A/G polymorphism located at À 29 nt of the 5 0 -untranslated region (located on chr3 at nt 3221430 and referenced as rs1672753). According to public databases (ucsc.genome.edu), the A allele is described as the ancestral allele from shrimp to human, although the G allele is notified as the reference allele. This GC-rich region was amplified as a 448-pb PCR product using the following primers: CRBN1F: 5 0 -GCAGGCCTGTAATTGTCCCT-3 0 and CRBN1R: 5 0 -GCAA-CAGAGCAGCGAAGAAA-3 0 in a GC-rich buffer as PCR mix. The distribution of A and G alleles in our cohort (67% and 33%, respectively) was not statistically different (P ¼ 0.095) from that of the general population as described (75.3% and 24.7%, respectively) in ucsc.genome.edu.
We then analyzed the impact of this CRBN A/G polymorphism according to the response to lenalidomide in low/int-1 MDS patients without del(5q). We found that 8 (57%) of the 14 responders had the G allele (all A/G) versus 9 (24%) of the 37 nonresponders (one G/G and 8 A/G). The crude odds ratio for response to treatment in the G allele group with reference to the A allele group was equal to 4.14 (95% confidence interval: 1.17-14.76), thus significantly different from 1 (P ¼ 0.045). In order to investigate potential confusion bias, differences for clinical and hematological characteristics between the G and the A allele groups were studied. No sex (P ¼ 0.674) or age (P ¼ 0.624) difference was found, and a trend (P ¼ 0.057) for an increased proportion of int-1 IPSS status in the G allele group (11/17 ¼ 64%) compared with the A allele group (12/33 ¼ 36%) was observed. This suggests that the best response rate in the group of patients with G allele is not linked to a more favorable IPSS.
Among the 51 patients of our cohort, bone marrow mononuclear cell RNA was available before treatment for 36 patients (22 nonresponders and 14 responders). CRBN gene expression level was analyzed by using an reverse transcriptase quantitative PCR strategy. The primers (CRBN_F in exon 7: 5 0 -CAAGAAACAGCTACGT GAATGG-3 0 , CRBN_R in exon 8:
allowed the detection of the full-length transcript (NM_016302.3) and two other transcripts including CRBN-002, whose upregulation is predictive of the response to thalidomide in myeloma. 12 Normalized relative quantities were calculated by using ACTIN, HPRT1 and UBC as reference genes. No statistical difference in the CRBN gene expression level was observed between responders and nonresponders. Although the rs1672753 polymorphism was located within a target region for transcription factors, the G allele (n ¼ 12) was not associated with a different level of CRBN mRNA in comparison to the A allele (n ¼ 24). These preliminary data indicate that, unlike current observation in myeloma, the CRBN expression level does not seem to be involved in the mechanism of response to lenalidomide in low/int-1 MDS without del(5)q. In this study, we have identified a relevant molecular biomarker that could predict the response to lenalidomide in low/int-1 MDS without del(5q). Previous studies showed that a favorable karyotype or a molecular signature consisting of a set of downregulated erythroid-specific genes is predictive of response in these patients. 13, 14 Although IMiDs directly inhibit CRBN, we could not exclude that these drugs may target other molecules, notably in MDS with del(5q). Indeed, secondary resistance to lenalidomide in MDS with del(5q) was found to be associated with overexpression of CDC25C. 15 Further studies are required in larger cohorts to confirm our findings and to investigate the biological consequences of CRBN polymorphism.
CONFLICT OF INTEREST
VS is consultant for Celgene, Janssen and Novartis. PF is consultant for Celgene, Ortho Biotech, Roche, Novartis, Cephalon, Epicept, Amgen, and Merck. FD is consultant for Novartis. MF is consultant for Celgene In the hematopoietic system, a role for Wnt signaling was first demonstrated during T-cell development in the thymus. 3-8 These differences might be explained by different levels of Wnt pathway activation. By using various targeted hypomorphic Apc alleles and a conditional deletion allele of Apc, which generates different Wnt signaling levels, it has been shown that different, lineage-specific Wnt dosages regulate HSCs, myeloid precursors and T lymphoid precursors during hematopoiesis. 9 The Tcf7 gene is a complex gene of which several different isoforms, including isoforms that lack the b-catenin binding domain, have been found. Tcf7 has been reported to be a b-catenin-Tcf7l2 target gene and to act as a feedback repressor of b-catenin-Tcf7l2 target genes. In this way, Tcf7 may assist Apc to suppress malignant transformation of epithelial cells.
10 Tcf7 expression is most abundantly expressed in T-lymphocytes, but is also expressed in HSCs.
11,12 B6-Tcf7-deficient mice develop a progressive block in the early thymocyte development, but are fully immunocompetent and live for over 1 year. 2, 13 Here, we report the impact of loss of Tcf7 on HSC and progenitor cells in vitro and in vivo. 
